An eighteen-month follow-up study on the effects of intravitreal dexamethasone implant in diabetic macular edema refractory to anti-VEGF therapy

International Journal of Ophthalmology

Volumn 9, Issue 10, 2016, Pages 1427-1432

  Pacella, Fernanda ^a   Romano, Maria Rosaria ^b   Turchetti, Paolo ^c   Tarquini, Giovanna ^d   Carnovale, Anna ^d   Mollicone, Antonella ^a   Mastromatteo, Alessandra ^a   Pacella, Elena ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Anti vascular endothelial growth factor therapy; Diabetic macular edema; Intravitreal dexamethasone implant

Indexed keywords

EID: 84991643953     PISSN: 22223959     EISSN: 22274898     Source Type: Journal    
DOI: 10.18240/ijo.2016.10.10     Document Type: Article

References (39)

1. Patelli F. Radice P, Giacomotli E. Diabetic macular edema. Ophthalmol 2014:54:164-173.
2. Zhang C, Wang H, Nie J, Wang F. Protective factors in diabetic retinopathy: focus on blood-retinal barrier. Discov Med 2014;18 (98): 105-112.
3. Zandbergen AA, Vogt L, de Zeeuw D, Lamberts SW, Ouwendijk RJ, Baggen MG, Bootsma AH. Change in albuminuria is predictive of cardiovascula r outcome in normotensive patients with type 2 diabetes and microalbuminuria. Diabetes Care 2007;30(12):3119-3121.
4. Soørensen VR, Mathiesen ER, Watt T, Bjorner JB, Andersen MV, Feldt-Rasmussen B. Diabetic patients treated with dialysis:complications and quality of life. Diahetolgia 2007;50(11):2254-2262.
5. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol 2009;54 (1) 1-32.
6. Funatsu H, Yamashita H, Noma H, Mimura T, Yamashita T, Hori S. Increasedlevelsofvascularendothelialgrowthfactorandinterleukin-6in the aqueous humor of diabetics with macular edema. Am J Ophthalmol 2002;133(1):70-77.
7. Noma H, Funatsu H, Mimura T, Harino S, Hori S. Vitreous levels of interleukin-6 and vascular end othelial growth factor in macular edema with central retinal vein occlusion. Ophthalmology 2009;116(1):87-93.
8. Agarwal A, Afridi R, Hassan M, Sadiq MA, Sepah YJ, Do DV, Nguyen QD. Novel therapies in development for diabetic macular edema. Curr Diab Rep 2015;15(10):75.
9. Adelman R, Parnes A, Michalewska Z, Parolini B, Boscher C, Ducournau D. Strategy for the management of diabetic macular edema:the European vitreo-retinal society macular edema study. Biomed Res Int 2015;2015: 352487.
10. Owen LA, Hartnett ME. Soluble media to rs of diabetic macular edema: the diagnostic role of aqueous VEGF and cytokine levels in diabetic macular edema. Curr Diab Rep 2013;13(4):476-480.
11. Bandello F, Preziosa C, Querques G, Lattanzio R. Update of intravitreal steroids for the treatment of diabetic macular edema. Ophthalmic Res 2014;52(2):89-96.
12. Saraiya NV, Goldstein DA. Dexamethasone for ocular inflammation. Expert Opin Pharmacother 2011;12(7): 1127-1131.
13. Bhagat R, Zhang J, Farooq S, Li XY. Comparison of the release profile and pharmacokinetics of intact and fragmented dexamethasone intravitreal implants in rabbit eyes. J Ocul Pharmacol Ther 2014;30(10):854-858.
14. Kim H, Lee JM, Park JS, Jo SA, Kim YO, Kim CW, Jo I. Dexamethasone coordinately regulates angiopoietin-1 and VEGF: a mechanism of glucocorticoid-induced stabilization of blood-brain barrier. Biochem Biophys Res Commun 2008;372(1):243-248.
15. Tamura H, Miyamoto K, Kiryu J, Miyahara S, Katsuta H, Hirose F, Musashi K, Yoshimura N. Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci 2005;46(4): 1440-1444.
16. Edelman JL. Differentiating intraocular glucocorticoids. Ophthahnologica 2010;224(Suppl 1):25-30.
17. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM; OZURDEXGENEVAStudy Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with maculared emadueto retinal vein occlusion. Ophthalmology 2010;117(6):1134-1146.
18. Stewart MW. Corticosteroidusefordiabeticmacularedema:oldfador new trend? Curr Diab Rep 2012;12(4):364-375.
19. Sorkin N, Loewenstein A, Habot-Wilner Z, Goldstein M. Intravitreal Dexamethasone Implant in patients with persistent macularedema of variable etiologies. Ophthahnologica 2014;232(2):83-91.
20. Sharareh B, Gallemore R, Taban M, Onishi S, Wallsh J. Recalcitrant macular edema after intravitreal bevacizumab is responsive to an Intravitreal Dexamethasone Implant in retinal vein occlusion. Retina 2013; 33(6):1227-1231.
21. Haller JA, Kuppermann BD, Blumenkranz MS, Williams GA, Weinberg DV, Chou C, Whitcup SM; Dexamethasone DDS Phase II Study Group. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 2010;128(3):289-296.
22. Mastropasqua R, Toto L, Borrelli E, Di Antonio L, De Nicola C, Mastrocola A, Di Nicola M, Carpineto P. Morphology and function over a one-year follow upperiod after Intravitreal Dexamethasone Implant (Ozurdex) in patients with diabetic macular edema. PLo SOne 2015;10(12): e0145663.
23. Pacella F, Ferraresi AF, Turchetti P, Lenzi T, Giustolisi R, Bottone A, Fameli V, Romano MR, Pacella E. Intravitreal injection of Ozurdex (®) implant in patients with persistent diabetic macular edema, withsix-month follow-up. Ophthalmol Eye Dis 2016;8:11-16.
24. Lazic R, Lukic M, Boras I, Draca N, Vlasic M, Gabric N, Tomic Z. Treatment of anti-vascular endothelial growth factor-resistant diabetic macular edema with dexamethasone intravitreal implant. Retina 2014;34 (4):719-724.
25. Querques G, Lattanzio R, Querques L, Triolo G, Cascavilla ML, Cavallero E, Del Turco C, Casalino G, Bandello F. Impact of Intravitreal Dexamethasone Implant (Ozurdex) on macular morphology and function. Retina 2014;34(2):330-341.
26. Rishi P, Rishi E, Kuniyal L, Mathur G. Short-term results of Intravitreal Dexamethasone Implant (OZURDEX ®) in the treatment of recalcitrant diabetic macular edema: a case series. Oman J Ophthalmol 2012;5(2): 79-82.
27. Pacella E, Vestri AR, Muscella R, Carbotti MR, Castellucci M, Coi L, Turchetti P, Pacella F. Preliminary results of an Intravitreal Dexamethasone Implant (Ozurdex) in patients with persistent diabetic macular edema. Clin J Ophthalmol 2013;7:1423-1428.
28. Zalewski D, Raczynska D, Raczynska K. Five-month observation of persistent diabetic macular edema after intravitreal injection of Ozurdex implant. Mediators Inflamm 2014;2014:364143.
29. Pacella E, La Torre G, Turchetti P, Merisola C, Lenzi T, Mazzeo F, Lucchetti P, Casale S, Pacella F. Evaluation ofe fficacy dexamethasone intravitreal implant compared to treatment with an ti-VEGF in the treatment of diabetic macular edema. Senses Sci 2014;1:164-168.
30. Gillies MC, Simpson JM, Gaston C, Hunt G, Ali H, Zhu M, Sutter F. Five-year result so far and omized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology 2009;116(11):2182-2187.
31. Campochiaro PA, Brown DM, Pearson A, Ciulla T, Boyer D, Holz FG, Tolentino M, Gupta A, Duarte L, Madreperla S, Gonder J, Kapik B, Billman K, Kane FE;FAMEStudy Group. Long-term benefit of sustained-delivery fluocinoloneacet on idevitreous in sertsfor diabetic macular edema. Ophthalmology 2011;118(4):626-635.
32. Stahn C, Buttgereit F. Genomic and non genomic effects of glucocorticoids. JVat CHn Pract Rheumatol 2008;4(10):525-533.
33. Campochiaro PA, Brown DM, Pearson A, Chen S, Boyer D, Ruiz-Moreno J, Garretson B, Gupta A, Hariprasad SM, Bailey C, Reichel E, Soubrane G, Kapik B, Billman K, Kane FE, Green K;FAME Study Group. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for atleast 3 years in patients with diabetic macular edema. Ophthalmology 2012;119(10):2125-2132.
34. Bandello F, Battaglia Parodi M, Tremolada G, Lattanzio R, De Benedetto U, Iacono P. Steroids as part of combination treatment:the future for the management of macular edema? Ophthahnologica 2010;224 (suppl 1): 41-45.
35. Kuppermann BD, Blumenkranz MS, Haller JA, Williams GA, Weinberg DV, Chou C, Whit cup SM; Dexamethasone DDSPhase IIStudy Group. Randomized controlled study of an intravitreous dexamethasonedrug delivery system in patients with persistent macular edema. Arch Ophthahnol 2007;125(3):309-317.
36. Boyer DS, Yoon YH, Belfort RJr, Bandello F, Maturi RK, Augustin AJ, Li XY, Cui H, Hashad Y, Whit cup SM; Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implantin patients with diabetic maculare dema. Ophthalmology2014;121(10):1904-1914.
37. Bandello F, Zarbin MA, Lattanzio R, Zucchiatti I. Clinical strategies in the management of diahetic retinopathy; a step-hy-step guide £>r ophthalmologists. Berlin: Springer; 2013.
38. Panozzo G, Gusson E, Panozzo G, Dalla Mura G. Dexamethasone in travit real implant for diabetic macular edema. in dications for a PRN regimen of treatment. Eur J Ophthalmol 2015;25(4):347-351.
39. Querques G, Darvizeh F, Querques L, Capuano V, Bandello F, Souied EH. Assessment of thereal-life usage of intravitreal dexamethasone implant in the treatment of chronic diabetic macular edema in France. J Ocul Pharmacol Ther 2016;32(6):383-389.